| Trial ID: | L2273 |
| Source ID: | NCT05173025
|
| Associated Drug: |
Fimasartan
|
| Title: |
Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension
|
| Acronym: |
FAoRAS
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypertension|Atherosclerosis|Diabetes Mellitus, Type 2|Renin Hypertension
|
| Interventions: |
DRUG: Fimasartan
|
| Outcome Measures: |
Primary: Angiotensin(1-7), Changes of serum angiotensin(1-7) at week 12 from baseline, 12 weeks | Secondary: Blood pressure, Change in blood pressure from baseline to week 12 Change in blood pressure from baseline to week 24 Change in blood pressure from baseline to week 24, 12 weeks|ACE-2, Change in ACE-2 from baseline to week 12 Change in blood pressure from baseline to week 24 Change in blood pressure from baseline to week 24, 12 weeks|ACE, Change in ACE from baseline to week 12 Change in blood pressure from baseline to week 24 Change in blood pressure from baseline to week 24, 12 weeks|Renin, Change in renin from baseline to week 12 Change in blood pressure from baseline to week 24 Change in blood pressure from baseline to week 24, 12 weeks|angiotensin, Change in angiotensin from baseline to week 12 Change in blood pressure from baseline to week 24 Change in blood pressure from baseline to week 24, 12 weeks|atherosclerosis, Change in atherosclerosis from baseline to week 12 Change in blood pressure from baseline to week 24 Change in blood pressure from baseline to week 24, 12 weeks|Muscle mass, Change in muscle mass from baseline to week 12 Change in blood pressure from baseline to week 24 Change in blood pressure from baseline to week 24, 12 weeks|Fat mass, Change in fat mass from baseline to week 12 Change in blood pressure from baseline to week 24 Change in blood pressure from baseline to week 24, 12 weeks|HbA1c, Change in HbA1c from baseline to week 12 Change in blood pressure from baseline to week 24 Change in blood pressure from baseline to week 24, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Seoul National University Bundang Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
42
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2018-01-01
|
| Completion Date: |
2023-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2023-08-14
|
| Locations: |
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, 463-707, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT05173025
|
